Redeye provides an initial take following SciBase’s Q3 2026 report. Overall, we view the report positively, as sales came in somewhat above our expectations, although costs were also slightly higher than expected. As anticipated, there were no deliveries to Castle Biosciences during the quarter, which explains both the slight q/q decline in sales and the clear improvement in gross margin. We will shortly release a research update, in which we expect to make only fine-tuning adjustments to our estimates.
LÄS MER
